FFC#12/2014

Inhalable dry powders for chemically-modified human Cationic AntiMicrobial Peptides (CAMPs): moving toward in vivo application

FFC#12/2014

Inhalable dry powders for chemically-modified human Cationic AntiMicrobial Peptides (CAMPs): moving toward in vivo application

PRINCIPAL INVESTIGATOR

Eugenio Notomista (Dip. di Biologia, Università di Napoli “Federico II”)

Partner

Francesca Ungaro (Dip. di Farmacia, Università di Napoli “Federico II”)

RESEARCHERS

15

CATEGORY

AREA 3 Bronchopulmonary infection

DURATION

1 year

GOAL

€ 22.000

RESULTS

Intra-tracheal administration to mice by the Penn Century MicroSprayerR Aerosolizer of rhodamine-labeled mhLYS showed that the distribution among lung lobes was asymmetric (rhodamine was always found only in 1 or 2 lobes of the right lung) and heterogeneous suggesting that a poor distribution may have contributed to low safety and efficacy showed by CAMP-RPs. Moreover, we produced NEM whose properties are well suited for the direct administration to bronchi/bronchioles of colistin, a model CAMP. Similarly to the results obtained using the aerosolizer, the distribution by a special insufflator of the fluorescently-labeled CAMP-RP in lung lobes was asymmetric and heterogeneous. Our results suggest that intra-tracheal administration of powders in mice requires further improvement before it is possible to perform a reliable efficacy test in vivo.

OTHER RESULTS

FFC #3/2024

Two molecules are effective in activating Heat Shock Proteins and enhancing the action of CFTR correctors with the F508del mutation in vitro.

FFC#5/2024

Some peptide nucleic acids (PNAs) re-sensitise Pseudomonas aeruginosa to the antibiotic meropenem in vitro and reduce its virulence.

FFC#1/2023

Tezacaftor, one of the components of Kaftrio, induces an accumulation of dihydroceramides both in vitro and in vivo in animal models